-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $34

Benzinga·03/18/2025 11:17:58
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $40 to $34.